9 Things to Know About Urolithin A and Why Menopause Researchers Are Watching It for Muscle and Mitochondrial Health
The fatigue that showed up in perimenopause wasn't the tired-after-a-long-day kind — it was something deeper, like the body's engine was misfiring no matter how much sleep happened. Learning that this could be mitochondrial, not just hormonal, reframed everything. Urolithin A didn't feel like hype once the mechanism made sense — it felt like a reasonable question worth asking.
Learn more about Rose →Mitochondria are at the center of why menopause fatigue feels different
Estrogen plays a direct role in supporting mitochondrial function — it helps regulate the production of ATP, the energy currency cells run on. When estrogen declines during perimenopause and menopause, mitochondrial efficiency drops alongside it, contributing to the deep, cellular fatigue that many women describe as unlike anything they experienced before. This isn't tiredness that a good night's sleep fixes; it reflects changes happening at the level of individual cells throughout the body, including in muscle tissue.
Urolithin A is not a nutrient you eat directly — your gut makes it
Urolithin A is a postbiotic: it is produced when specific gut bacteria metabolize ellagitannins, a type of polyphenol found in pomegranates, walnuts, raspberries, and strawberries. The catch is that only roughly 30–40% of people carry the gut microbiome composition needed to produce meaningful amounts of urolithin A from food alone. This means that two women eating identical diets can have dramatically different urolithin A levels, which partly explains why the supplement form has attracted research interest as a way to deliver the compound more reliably.
Mitophagy is the cellular housekeeping process urolithin A appears to switch on
Mitophagy is a specialized form of autophagy — the body's system for identifying and recycling damaged or dysfunctional cellular components. Specifically, it targets mitochondria that are no longer working properly, breaking them down so their parts can be reused and new, healthier mitochondria can form. Research, including work published in Nature Metabolism, has shown that urolithin A can activate this process in human muscle cells, effectively acting as a quality-control signal that aging and declining hormones appear to dampen over time.
The first human clinical trial showed real changes in muscle gene expression
A 2019 randomized controlled trial published in Nature Metabolism tested urolithin A supplementation in older adults and found significant upregulation of genes involved in mitochondrial biogenesis and mitophagy in skeletal muscle, compared to placebo. Participants taking the supplement also showed improvements in aerobic endurance as measured by distance walked in six minutes. This was a relatively small trial — 66 participants — but it was placebo-controlled and double-blinded, which gives it more weight than most early supplement research carries.
A 2022 trial in middle-aged adults added muscle strength data to the picture
A follow-up double-blind RCT published in JAMA Network Open enrolled 88 adults aged 40–65 and found that those taking urolithin A for four months showed improvements in muscle endurance and a statistically significant increase in mitochondrial gene markers compared to placebo. Importantly, this age group overlaps heavily with perimenopause, and the strength-related outcomes are particularly relevant given that women lose muscle mass at an accelerated rate once estrogen begins to decline. The researchers noted the supplement was well tolerated with no significant adverse events.
There is no dedicated clinical trial in perimenopausal or menopausal women yet
This is an important gap that honest reporting requires flagging: the existing human trials have enrolled older adults or mixed-age groups, and none have been designed specifically to study urolithin A's effects in women during the menopausal transition. Hormonal status was not a primary variable in any published trial to date, which means the promising results cannot be directly extrapolated to perimenopause without assumption. Researchers at several institutions have noted this gap publicly, and menopause-specific trials are considered a logical next step.
Animal studies suggest urolithin A may have direct interactions with estrogen-related pathways
Preclinical research in rodent models has found that urolithin A may activate pathways that partially overlap with estrogen receptor signaling, particularly in muscle and bone tissue, though researchers are careful to note this does not make it estrogenic in the clinical sense. Some animal studies have shown it may support bone density markers and reduce inflammation in ways that partially mimic estrogen's protective roles — outcomes that are highly relevant to menopause but remain unconfirmed in human trials. These findings are intriguing enough that they are driving the design of future studies, but they should not be read as proof of effect in women.
Urolithin A may also support the kind of low-grade inflammation that menopause amplifies
Declining estrogen is associated with an increase in systemic low-grade inflammation — sometimes called inflammaging — which contributes to joint pain, brain fog, and accelerated muscle breakdown. Urolithin A has demonstrated anti-inflammatory properties in multiple cell and animal studies, including suppression of NF-κB signaling, a key driver of inflammatory cascades. While human anti-inflammatory data is still limited, the mechanism is plausible and consistent with the broader picture of mitochondrial and cellular health it appears to support.
Eating more ellagitannin-rich foods is the no-risk starting point while the evidence matures
Pomegranate seeds and juice, walnuts, raspberries, blackberries, and strawberries are the richest food sources of the ellagitannins that gut bacteria convert into urolithin A — and they carry their own independent benefits regardless of conversion rate. For the roughly 60–70% of people who are not efficient urolithin A producers from food alone, the supplement form used in the clinical trials delivers the compound directly and has shown a clean safety profile in human studies so far. Women considering the supplement form should discuss it with a healthcare provider who understands their full picture, particularly if they are managing other menopause-related conditions or taking medications.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.